Efficacy and safety of Dimdazenil in the adult insomnia patients: a phase II randomized, multicenter, double-blind, placebo-controlled, and parallel-group study
Wirksamkeit und Sicherheit von Dimdazenil bei erwachsenen Patient:innen mit Insomnie: Phase-II-RCT, multizentrisch, doppelblind, placebokontrolliert, Parallelgruppenstudie
SLEEP · 08.02.2024 · 47 (2)
DOI: 10.1093/sleep/zsad271 ↗Auf einen Blick
Bei Erwachsenen mit Insomnie verbesserte Dimdazenil mehrere objektive und subjektive Schlafparameter gegenüber Placebo. Für einzelne Dosen waren die Effekte zeitabhängig.
Fragestellung
Wirkt Dimdazenil bei Erwachsenen mit Insomnie wirksam und sicher im Vergleich zu Placebo?
Methode
Randomisierte, doppelblinde, placebokontrollierte Parallelgruppenstudie; 18–65 Jahre; orale Gabe von Placebo oder Dimdazenil 1,5, 2,5 oder 5 mg für 14 Tage.
Ergebnisse
288 Patient:innen erhielten mindestens 1 Dosis. TST besser unter 1,5, 2,5 und 5 mg an Tag 1/2; an Tag 13/14 unter 2,5 und 5 mg. LPS, SE und subjektive Schlafparameter verbesserten sich teils dosisabhängig. Häufigste TEAEs: Schwindel, Vertigo, Schwäche.
Schlussfolgerung der Autor:innen
Dimdazenil 1,5, 2,5 und 5 mg verbesserte bestimmte objektive und subjektive Schlafparameter bei guter Sicherheitsverträglichkeit. Die Autor:innen sehen es als potenziell neue Behandlung der Insomnie.
Kernaussagen
- TST verbessert unter allen 3 Dosen an Tag 1/2
- An Tag 13/14 blieben 2,5 und 5 mg wirksam
- Häufigste TEAEs: Schwindel, Vertigo und Schwäche
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift SLEEP, online erschienen am 21.10.2023. Verfasst von Yanpeng Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, Shanghai Changzheng Hospital, Shanghai, China. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Schlaf
Abstract (Originalsprache)
Study Objectives To evaluate the efficacy and safety of Dimdazenil, a positive allosteric modulator with selectivity for α1, α5 subunit-containing GABAA receptors, on sleep variables in patients with insomnia disorder.
Methods
In this randomized, double-blind, placebo-controlled trial, adults (18–65 years) with insomnia disorder were randomized (1:1:1:1 to receive daily oral placebo, Dimdazenil (1.5, 2.5, or 5 mg) for 14 days. The primary efficacy outcome was the total sleep time (TST) on day 1/2 and day 13/14, measured by polysomnography. The secondary outcome measures included (1) latency to persistent sleep (LPS), sleep efficiency (SE), wake after sleep onset (WASO) and number of awakenings (NAW) on days 1/2 and day 13/14, and (2) the average subjective sleep latency (sSL), total sleep time (sTST), wake after sleep onset (sWASO) and number of awakenings (sNAW) recorded in sleep diary and sleep questionnaire, and the evaluation of insomnia severity index. Rebound insomnia, withdrawal, and treatment-emergent adverse events were also assessed.
Results
Of 569 patients screened, 288 (76.4% female) were randomized and received one dose. For the primary outcomes, TST was significantly improved in the Dimdazenil 1.5, 2.5, and 5 mg group compared with the placebo group at day 1/2, and significantly improved in the Dimdazenil 2.5 and 5 mg groups compared with the placebo group at day 13/14. The Least Squares Means (standard errors) and 95% Confidence Intervals for the three active doses compared to placebo are 25.5 (8.31), (9.16, 41.89) for the 1.5 mg dose; 17.4 (8.19), (1.29, 33.55) for the 2.5 mg dose; 22.8 (8.15), (6.72, 38.80) for the 5 mg dose on day 1/2. Corresponding data on day 13/14 are 7.6 (8.07), (−8.24, 23.53) and 19.3 (8.06), (3.43, 35.17) and 18.2 (7.95), (2.49, 33.80). LPS was significantly reduced in the Dimdazenil 5 mg group compared with the placebo group on day 1/2. SE was significantly improved in the Dimdazenil 1.5 and 5 mg group compared with the placebo group at day 1/2. In the subjective sleep parameters, sSL on average was significantly lower in the Dimdazenil 1.5, 2.5, and 5 mg groups compared with the placebo group. sTST on average was significantly higher in the Dimdazenil 1.5, 2.5, and 5 mg groups compared with the placebo group. The most common TEAEs were dizziness, vertigo, and weakness with no clinically relevant treatment-related serious adverse events.
Conclusions
Dimdazenil of 1.5, 2.5, and 5 mg improved certain objective and subjective sleep outcomes in people with insomnia disorder, with a favorable safety profile. These findings suggested that Dimdazenil may represent a promising new treatment for insomnia disorder, a prevalent condition with limited effective and safe treatments available. Clinical Trial Information A multicenter, randomized, double-blind, multidose, placebo parallel controlled phase II clinical study of EVT201 in the treatment of insomnia disorders (http://www.chinadrugtrials.org), with the number of CTR20150664.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology Department, Shanghai Changzheng Hospital, Shanghai, China.
- Shanghai Research Institute, Zhejiang Jingxin Pharmaceutical Co., Ltd, Shanghai, China.
- The president's office, Zhejiang Jingxin Pharmaceutical Co., Ltd, Zhejiang, China.
Zitieren
APA
Li, Y., Zhang, R., Zhou, Y., Bao, C., Lin, Z., Chen, C., He, J., Jin, Z., Song, L., Zhang, M., Guo, S., Jiang, Y., & Zhao, Z. (2024). Efficacy and safety of Dimdazenil in the adult insomnia patients: a phase II randomized, multicenter, double-blind, placebo-controlled, and parallel-group study. SLEEP, 47(2). https://doi.org/10.1093/sleep/zsad271
Vancouver
Li Y, Zhang R, Zhou Y, Bao C, Lin Z, Chen C, et al. Efficacy and safety of Dimdazenil in the adult insomnia patients: a phase II randomized, multicenter, double-blind, placebo-controlled, and parallel-group study. SLEEP. 2024;47(2). doi:10.1093/sleep/zsad271
BibTeX
@article{Li2024,
author = {Li, Yanpeng and Zhang, Ruoxi and Zhou, Yanling and Bao, Cungang and Lin, Zhaocun and Chen, Chunyan and He, Jingjing and Jin, Zhiping and Song, Lihua and Zhang, Min and Guo, Sigen and Jiang, Yu and Zhao, Zhongxin},
title = {Efficacy and safety of Dimdazenil in the adult insomnia patients: a phase II randomized, multicenter, double-blind, placebo-controlled, and parallel-group study},
journal = {SLEEP},
year = {2024},
volume = {47},
number = {2},
doi = {10.1093/sleep/zsad271}
}
EUVIMED